滚动资讯
AgilentAgilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma - BioSpaceLonza NewsLonza opens Media Development Lab in Singapore for cell culture media optimisation - BioSpectrum AsiaIlluminaIllumina Inc. Stock: Dominant Player in Genomic Sequencing Faces Competitive and Regulatory Challeng - AD HOC NEWSEndpoints NewsTop HHS official makes impassioned pitch to take on China biotechThermo FisherAssessing Thermo Fisher Scientific (TMO) Valuation After SHL Medical Alliance And U.S. Capacity Expansion - Yahoo FinanceIlluminaA Look At Labcorp Holdings (LH) Valuation After Illumina Alliance Puts Precision Oncology In Focus - simplywall.stIlluminaDRAGEN v4.5: Expanding Accurate Variant Discovery Across the Entire Genome - IlluminaThermo FisherIs It Time To Reassess Thermo Fisher Scientific (TMO) After Recent Share Price Weakness? - simplywall.stCellSTING signaling modulation by COPII cargo recognitionCellDevelopment of non-spatial grid-like neural codes tracks inference and intelligenceFierceBiotechCMR Surgical kicks off Versius Plus robot’s US commercial launchAgilentVanguard disaggregates holdings after realignment — Agilent (NYSE: A) - Stock Titan
BioWorld 2025年12月22日

FDA批准Cytokinetics公司药物aFICamten（现名Myqorzo）用于治疗oHCM。

FDA批准Cytokinetics公司药物aFICamten（现名Myqorzo）用于治疗oHCM。

原文
暂时没有全文，请查看原始来源。

目录

59 全部